Prostamax, a synthetic peptide copying a bull-prostate extract, is sold as an injectable research product for prostate health with age. Two small patient groups in the developer's patent report less pelvic pain, urinary and sexual problems; no randomized human trial or independent check exists. No serious harm is documented, reflecting absent human study as much as safety; product quality, lab hints of genetic damage and delayed cancer diagnosis are concerns. (Full Review)
| Marker | Target | Why |
|---|---|---|
| PSA (total) | <2.5 ng/mL (age 40–59); stable year to year | Cancer and enlargement screen |
| Free-PSA fraction | >25% of total PSA | Separates benign from suspicious elevations |
| IPSS | 0–7 (mild) | Tracks urinary symptoms |
| NIH-CPSI | ≤9; drop ≥6 points from baseline | Tracks prostatitis pain and urinary symptoms |
| Peak urine flow (Qmax) | >15 mL/s | Objective obstruction measure |
| Post-void residual | <50 mL | Detects incomplete emptying |
| Urinalysis | No leukocytes, nitrites or blood | Excludes infection and bleeding |
| Creatinine and eGFR | eGFR >90 mL/min/1.73 m² | Detects obstruction-related kidney strain |
| Complete blood count | Hemoglobin 14–16 g/dL; platelets 150–350 ×10³/µL | Baseline for infection and bleeding risk |
| Prostate volume (ultrasound) | 20–30 mL | Tracks enlargement over time |
Cadence: Baseline before a first course; symptom scores at the end of each course and again at 4–6 weeks; PSA and uroflowmetry at 3 months, then every 6–12 months while courses continue